<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742833/" ref="ordinalpos=4375&amp;ncbi_uid=5197058&amp;link_uid=PMC3742833" image-link="/pmc/articles/PMC3742833/figure/F3/" class="imagepopup">Figure 3. FAM83B expression confers resistance to therapeutic inhibition of the PI3K/AKT <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span>.  From: FAM83B-mediated activation of PI3K/AKT and MAPK <span class="highlight" style="background-color:">signaling</span> cooperates to promote epithelial cell transformation and resistance to targeted therapies. </a></div><br /><div class="p4l_captionBody">(a) HME1 cells expressing GFP or FAM83B were plated in the presence and absence of a PI3K inhibitor LY294002 (1, 5, and 10 μM) and cell number quantified 5 days later. (b) HME1 cells expressing GFP or FAM83B were plated in the presence and absence of an AKT inhibitor MK2206 (1, 5, and 10 μM) and cell number quantified 5 days later.</div></div>